8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is aPKG (protein kinase G)activator. 8-Bromo-cGMP sodium significantly inhibitsCa²⁺macroscopic currents and impairsinsulinrelease stimulated with high K^+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses^[2].

8-Bromo-cGMP sodium (1-100 μM; 8 h) increases resistance of LLC-PK1 cells to CsA toxicity concentration-dependently^[3].
8-Bromo-cGMP sodium (1-100 μM; 16 h) induces the synthesis of HO-1 protein in a concentration-dependent fashion^[3].

8-Bromo-cGMP sodium (0.3, 1, 3.0 nmol; intrathecal administration; 10 min before test) dose-dependently and significantly increases the tail-flick latency in Vincristine-treated mice to the level observed in vehicle-treated naive mice (male ICR mice, 4weeks of age and weighing 20 g). Vincristine (0.05 mg/kg 1 day after the pre-drug tail-flick latency, and then 0.125 mg/kg twice a week for 6 weeks) can induce painful neuropathy in mice^[4].
8-Bromo-cGMP sodium (10 mg/kg; iv; single dose) results in vasodilator responses in eNOS-Tg mice and WT littermates in C57BL/6 background (19-35 g)^[5].

446.08

Solid

C₁₀H₁₀BrN₅NaO₇P

51116-01-9

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H₂O : 100 mg/mL(224.18 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (224.18 mM); Clear solution; Need ultrasonic